IP Library › Granted Patent US 12,410,156
Granted Patent B2
US 12,410,156 · App. 18/240,293 · Granted Sep 9, 2025

Kinase inhibitors

Inventors: Aleksandr Aliper (Moscow, RU); Vladimir Aladinskiy (Moscow, RU); Aleksandrs Zavoronkovs (Pak Shek Kok, HK)
Assignee: INSILICO MEDICINE IP LIMITED
C07D405/04A61K31/4164A61K31/4439A61K31/506C07D401/04C07D401/14C07D403/04C07D403/14C07D405/14C07D409/04C07D413/04C07D417/04C07D471/04C07D491/048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,156
App. No.
18/240,293
Granted
Sep 9, 2025
Kind
B2
Abstract

A TNIK and/or MAP4K4 kinase inhibitor can include: Formula A, derivative, prodrug, salt, stereoisomer, tautomer polymorph, or solvate thereof, or having chirality at any chiral center, wherein: ring 1 is an aromatic ring with or without hetero atoms; ring 2 is a hetero aromatic ring; ring 3 includes at least one hetero aromatic ring and optionally at least one cycloaliphatic ring fused with the at least one hetero aromatic ring; ring 4 is an aromatic ring with or without hetero atoms; Y is a bond or a linker; Y 1 is a linker; each n is independently 0, 1, or 2; each o is independently 0, 1, 2, 3, 4, or 5; each R 1 , R 6 , R 11 , and R 12 is independently a substituent; and R A is a ring structure, straight aliphatics, or branched aliphatics, which can be substituted or unsubstituted, any with or without hetero atoms.

Claims (49)

1. A compound of a structure of Formula A1, salt thereof, stereoisomer thereof, tautomer thereof, or solvate thereof,

wherein:

ring D is a polycycle consisting of an aromatic ring fused to a cyclic aliphatic;

each R 1 , R 2 , R 3 , R 4 , and R 5 is independently a hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, or trifluromethyloxy;

each R 6 , R 7 , R 8 , R 9 , or R 10 is independently hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinium, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, or morpholino;

each R 12 is hydrogen;

X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , and X 20 are independently C or N;

X 3 is NH, O, or S;

X 14 is NH or O;

Y 1 is an amide linker;

m is 1, 2, or 3; and

n is 0, 1, or 2;

a wherein when an X group is N in an aromatic ring, the R group bonded thereto is nothing.

2. The compound of claim 1 , wherein R 1 , R 2 , R 4 , and R 5 are each hydrogen and at least one of the following:

R 7 , R 8 , and R 10 are H;

R 7 , R 8 , R 9 , and R 10 are H;

R 6 , R 7 , R 9 , and R 10 are H; or

R 7 , R 9 , and R 10 are H.

3. The compound of claim 1 , wherein n is 0.

4. A compound of a structure of Formula 5B, salt thereof, stereoisomer thereof, tautomer thereof, or solvate thereof,

wherein:

each R 1 , R 2 , R 3 , R 4 , and R 5 is independently a hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, or trifluromethyloxy;

each R 6 , R 7 , R 8 , R 9 , or R 10 is independently hydrogen, F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinium, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, or morpholino;

each R 12 is hydrogen;

X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , and X 13 are independently C or N;

X 3 is NH, O, or S;

X 14 is NH or O;

Y 1 is an amide linker; and

n is 0, 1, or 2;

wherein when an X group is N in an aromatic ring, the R group bonded thereto is nothing.

5. The compound of claim 4 , wherein:

X 7 , X 8 , X 9 , and X 12 are independently C or N;

X 3 is NH, O, or S;

X 10 and X 11 are independently C or N; and

X 14 is NH or O;

wherein each of R 2 , R 3 , R 4 , R 8 , and R 12 is H.

6. The compound of claim 4 , wherein n is 0.

7. The compound of claim 4 , wherein R 6 and R 9 are independently F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinium, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, or morpholino;

R 1 , R 2 , R 4 , and R 5 are each hydrogen; and

R 7 , R 8 , and R 10 are H.

8. The compound of claim 7 , wherein R 6 is F, Br, Cl, I, methoxy, or methyl ester; and R 9 is F or methoxy.

9. The compound of claim 4 , wherein R 6 and R 8 are independently F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinium, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, or morpholino;

R 1 , R 2 , R 4 , and R 5 are each hydrogen; and

R 7 , R 9 , and R 10 are H.

10. The compound of claim 9 , wherein R 6 is F, Br, Cl, methoxy, or methyl ester; and R 8 is F, methoxy, or methyl.

11. The compound of claim 4 , wherein R 6 is F, Br, Cl, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, isopropyl, tert-butyl, trifluoromethyl, oxide, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, trifluromethyloxy, methylthio, ethylthio, propylthio, butylthio, pentylthio, hexylthio, heptylthio, octylthio, methylalcohol, ethylalcohol, propylalcohol, butylalcohol, pentylalcohol, hexylalcohol, heptylalcohol, octylalcohol, acetyl, carboxylic acid, alkyl carboxylic acid, methyl carboxylic acid, ethyl carboxylic acid, propionyl, butyryl, acetamide, methylacetamide, ethylacetamide, propionamide, butyramide, pentanamide, hexanamide, heptanamide, octanamide, fluoromethyl, bifluoromethyl, trifluoromethyl, fluoromethoxy, bifluoromethoxy, trifluoromethoxy, methyl ester, ethyl ester, propyl ester, butyl ester, pentyl ester, hexyl ester, heptyl ester, octyl ester, methylsulfanyl, thiomethyl, ethylsulfanyl, propylsulfanyl, butylsulfanyl, pentylsulfanyl, hexylsulfanyl, heptylsulfanyl, octylsulfanyl, sulfamoyl, methylpiperazinium, piperazinyl, hydroxyethylpiperazinyl, bis(2-hydroxyethyl)amino, or morpholino;

R 1 , R 2 , R 4 , and R 5 are each hydrogen; and

R 7 , R 8 , R 9 , and R 10 are H.

12. The compound of claim 11 , wherein R 6 is F, Br, Cl, methoxy, or methyl ester.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 68714 FRAME 155. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT OF ASSIGNORS INTEREST. Recorded Sep 27, 2024
From: ALIPER, ALEKSANDR; ALADINSKIY, VLADIMIR; ZAVORONKOVS, ALEKSANDRS
To: INSILICO MEDICINE IP LIMITED
Reel/Frame 069092/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2024
From: ALIPER, ALEKSANDR; ALADINSKIY, VLADIMIR; ZAVORONKOVS, ALEKSANDRS
To: INSILICO MEDICINE IP LIMITED
Reel/Frame 068714/0155 →
Continuity (3)
Continuation 16796864 · Feb 20, 2020
Provisional Application 62809413 · Feb 22, 2019
Related Publication 20240092764A1 · Mar 21, 2024
References Cited (52)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5563165A · Talley et al. · 1996 [cited by applicant]
US 5760068A · Talley et al. · 1998 [cited by applicant]
US 7314885B2 · Aronov et al. · 2008 [cited by applicant]
US 9556179B2 · Velaparthi et al. · 2017 [cited by applicant]
US 11739078B2 · Aliper et al. · 2023 [cited by applicant]
US 11795160B2 · Aliper et al. · 2023 [cited by applicant]
US 20030158238A1 · Hale et al. · 2003 [cited by applicant]
US 20040039198A1 · Bender et al. · 2004 [cited by applicant]
US 20040116416A1 · Laufer et al. · 2004 [cited by applicant]
US 20050272789A1 · Hale et al. · 2005 [cited by applicant]
US 20070105900A1 · Berdini et al. · 2007 [cited by applicant]
US 20090227588A1 · Fleck et al. · 2009 [cited by applicant]
US 20240092765A1 · Aliper et al. · 2024 [cited by applicant]
CN 1505625A · 2004 [cited by applicant]
CN 1505628A · 2004 [cited by applicant]
WO WO9747618A1 · 1997 [cited by applicant]
WO WO9847894A1 · 1998 [cited by applicant]
WO WO0157022A2 · 2001 [cited by applicant]
WO WO0240468A1 · 2002 [cited by applicant]
WO WO02088097A1 · 2002 [cited by applicant]
WO WO2006028958A2 · 2006 [cited by applicant]
WO WO2006089798A1 · 2006 [cited by applicant]
WO WO2010090716A1 · 2010 [cited by applicant]
WO WO2011025706A2 · 2011 [cited by applicant]
WO WO2012084678A1 · 2012 [cited by applicant]
WO WO2016038583A1 · 2016 [cited by applicant]
WO WO2019097515A1 · 2019 [cited by applicant]
WO WO2020051207A2 · 2020 [cited by applicant]
WO WO2020078362A1 · 2020 [cited by applicant]
WO WO2020170202A1 · 2020 [cited by applicant]
WO WO2020170203A1 · 2020 [cited by applicant]
WO WO2020219792A1 · 2020 [cited by applicant]
WO WO2020230134A1 · 2020 [cited by applicant]
WO WO2020230136A1 · 2020 [cited by applicant]
Carlson et al. Systematically Mitigating the p38α Activity of Triazole-based BET Inhibitors. ACS Med Chem Lett. 10(9):1296-1301 (2019). [cited by applicant]
Clark et al. Chemistry of micrococcin P. VII. Dimethyl micrococcinate and some synthetic pyridine-polythiazole carboxylic esters. J Chem Soc Perkin 1(16):1354-1356 (1966). [cited by applicant]
Eppstein et al. Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. PNAS USA 82(11):3688-3692 (1985). [cited by applicant]
European search report and opinion dated Nov. 16, 2022 for EP Application No. 20759579.4. [cited by applicant]
Hwang et al. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study. PNAS USA 77(7):4030-4034 (1980). [cited by applicant]
International search report with written opinion dated Jun. 4, 2020 for PCT/IB2020/051451. [cited by applicant]
International search report with written opinion dated Jun. 4, 2020 for PCT/IB2020/051452. [cited by applicant]
Registry No. 1349069-58-4, File Registry on STN, entered STN: Dec. 5, 2011. [cited by applicant]
Registry No. 1357751-66-6, File Registry on STN, entered STN: Feb. 28, 2012. [cited by applicant]
Registry No. 1359379-48-8, File Registry on STN, entered STN: Mar. 2, 2012. [cited by applicant]
Registry No. 214408-80-7, File Registry on STN, entered STN: Nov. 18, 1998. [cited by applicant]
Registry No. 254964-43-7, File Registry on STN, entered STN: Feb. 6, 2000. [cited by applicant]
Registry No. 667400-49-9, File Registry on STN, entered STN: Mar. 25, 2004. [cited by applicant]
STN search results, RN 1359379-48-8 . . . , RN951603-22-8, etc., entered STN: Mar. 2, 2012 ˜ Oct. 26, 2007 Structure formula. (46 pages). [cited by applicant]